Latest Lilly Stories
Anthem Blue Cross and Blue Shield and Indiana Family & Social Services Administration (FSSA)offer students insights on access to healthcare INDIANAPOLIS, June 23, 2014 /PRNewswire/
AWARD-2: Once-Weekly Dulaglutide 0.75 mg Non-Inferior, 1.5 mg Superior in HbA1c Reduction from Baseline with Sustained Weight Loss and Lower Risk for Hypoglycemia SAN FRANCISCO, June 16, 2014
Once-Weekly Dulaglutide 1.5 mg Also Demonstrates Weight Loss, Low Rates of Hypoglycemia in AWARD-6 Trial SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today
Companies present comprehensive data for LY2963016, investigational new insulin glargine product SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- For the first time today, Eli Lilly and Company
INDIANAPOLIS, June 11, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Phase III REACH trial of CYRAMZA(TM) (ramucirumab) in patients with hepatocellular carcinoma,
Company to highlight late-stage pipeline molecules, including once-weekly dulaglutide and basal insulin peglispro INDIANAPOLIS, June 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
· Data for investigational compounds LY2963016, empagliflozin and empagliflozin/linagliptin combination tablet highlight robust alliance pipeline RIDGEFIELD, Conn.
-- System is one of the largest for a pharmaceutical company worldwide, the largest for a pharmaceutical company in New Jersey -- BEDMINSTER, N.J., June 5, 2014 /PRNewswire/ -- KDC
-- REVEL Data Published in The Lancet, Presented at Annual ASCO Meeting -- CHICAGO, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from REVEL,
INDIANAPOLIS, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will begin sharing its clinical trial data with scientific researchers through
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.